XLXavier Ligneau

Xavier Ligneau

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Xavier Ligneau has a total of 65 co-authors. Here are the top co-authors by number of shared publications:

  • Holger Stark

    Institute of Pharmaceutical and Medicinal Chemistry Heinrich Heine University Düsseldorf Duesseldorf Germany

    8 shared publications
  • Jean-Charles Schwartz

    6 shared publications
  • Séverine Morisset-Lopez

    Centre de Biophysique Moléculaire (CBM), Centre National de la Recherche Scientifique (CNRS), Orléans, France

    5 shared publications
  • Walter Schunack

    Institut für Pharmazie, Freie Universität Berlin, Königin-Luise-Strasse 2+4, 14195 Berlin, Germany

    5 shared publications
  • Jean-Michel Arrang

    INSERM, U573, Centre Paul Broca, Paris, France

    4 shared publications
  • C. Robin Ganellin

    Unité de Neurobiologie et Pharmacologie Moléculaire (U573) de l'Institut National de la Santé et de la Recherche Médicale, Centre Paul Broca, 75014 Paris, France; Unité de Neurobiologie des Etats de Sommeils et d'Eveil (U480) de l'Institut National de la Santé et de la Recherche Médicale, Université Claude Bernard, 69373 Lyon Cedex 08, France; Laboratoire Bioprojet, 75002 Paris, France; Institut für Pharmazeutische Chemie, Johann Wolfgang Goethe-Universität, 60439 Frankfurt am Main, Germany;...

    3 shared publications

Latest Publications

  • Open Access

    Pitolisant, a wake‐promoting agent devoid of psychostimulant properties: Preclinical comparison with amphetamine, modafinil, and solriamfetol

    by Stéphane Krief, Isabelle Berrebi‐Bertrand, Isabelle Nagmar, Martin Giret, Simon Belliard, David Perrin, Marilyne Uguen, Philippe Robert, Jeanne‐Marie Lecomte, Jean‐Charles Schwartz, et al.

    Several therapeutic options are currently available to treat excessive daytime sleepiness (EDS) in patients suffering from narcolepsy or obstructive sleep apnea. However, there are no comparisons between the various wake‐promoting agents in terms of mechanism of action, efficacy, or safety. The goal of this study was to compare amphetamine, modafinil, solriamfetol, and pitolisant at their known primary pharmacological targets, histamine H3 receptors (H3R), dopamine, norepinephrine, and serotonin transporters, and in various in vivo preclinical models in relation to neurochemistry, locomotion, behavioral sensitization, and food intake. Results confirmed that the primary pharmacological effect of amphetamine, modafinil, and solriamfetol was to increase central dopamine neurotransmission, in part by inhibiting its transporter. Furthermore, solriamfetol increased levels of extracellular dopamine in the nucleus accumbens, and decreased the 3,4‐dihydroxyphenyl acetic acid (DOPAC)/DA ratio in the striatum, as reported for modafinil and amphetamine. All these compounds produced hyperlocomotion, behavioral sensitization, and hypophagia, which are common features of psychostimulants and of compounds with abuse potential. In contrast, pitolisant, a selective and potent H3R antagonist/inverse agonist that promotes wakefulness, had no effect on striatal dopamine, locomotion, or food intake. In addition, pitolisant, devoid of behavioral sensitization by itself, attenuated the hyperlocomotion induced by either modafinil or solriamfetol. Therefore, pitolisant presents biochemical, neurochemical, and behavioral profiles different from those of amphetamine and other psychostimulants such as modafinil or solriamfetol. In conclusion, pitolisant is a differentiated therapeutic option, when compared with psychostimulants, for the treatment of EDS, as this agent does not show any amphetamine‐like properties within in vivo preclinical models.


  • Open Access

    Nonclinical cardiovascular safety of pitolisant: comparing International Conference on Harmonization S7B and Comprehensive in vitro Pro‐arrhythmia Assay initiative studies

    by Xavier Ligneau, Rashmi R Shah, Isabelle Berrebi‐Bertrand, Gary R Mirams, Philippe Robert, Laurent Landais, Pierre Maison‐Blanche, Jean‐François Faivre, Jeanne‐Marie Lecomte, Jean‐Charles Schwartz

    Background and Purpose: We evaluated the concordance of results from two sets of nonclinical cardiovascular safety studies on pitolisant.Experimental Approach: Nonclinical studies envisaged both in the International Conference on Harmonization (ICH) S7B guideline and Comprehensive in vitro Pro‐arrhythmia Assay (CiPA) initiative were undertaken. The CiPA initiative included in vitro ion channels, stem cell‐derived human ventricular myocytes, and in silico modelling to simulate human ventricular electrophysiology. ICH S7B‐recommended assays included in vitro hERG (KV11.1) channels, in vivo dog studies with follow‐up investigations in rabbit Purkinje fibres and the in vivo Carlsson rabbit pro‐arrhythmia model.Key Results: Both sets of nonclinical data consistently excluded pitolisant from having clinically relevant QT‐liability or pro‐arrhythmic potential. CiPA studies revealed pitolisant to have modest calcium channel blocking and late INa reducing activities at high concentrations, which resulted in pitolisant reducing dofetilide‐induced early after‐depolarizations (EADs) in the ICH S7B studies. Studies in stem cell‐derived human cardiomyocytes with dofetilide or E‐4031 given alone and in combination with pitolisant confirmed these properties. In silico modelling confirmed that the ion channel effects measured are consistent with results from both the stem cell‐derived cardiomyocytes and rabbit Purkinje fibres and categorized pitolisant as a drug with low torsadogenic potential. Results from the two sets of nonclinical studies correlated well with those from two clinical QT studies.Conclusions and Implications: Our findings support the CiPA initiative but suggest that sponsors should consider investigating drug effects on EADs and the use of pro‐arrhythmia models when the results from CiPA studies are ambiguous.


  • Preclinical evaluation of the abuse potential ofPitolisant, a histamineH3receptor inverse agonist/antagonist compared withModafinil

    by M Uguen, D Perrin, S Belliard, X Ligneau, Pm Beardsley, Jm Lecomte, Jc Schwartz

    Background and Purpose: Pitolisant, a histamineH3receptor inverse agonist/antagonist is currently underPhaseIIIclinical trials for treatment of excessive daytime sleepiness namely in narcoleptic patients. Its drug abuse potential was investigated usingin vivomodels in rodents and monkeys and compared with those ofModafinil, a psychostimulant currently used in the same indications.Experimental Approach: Effects ofPitolisant on dopamine release in the nucleus accumbens, on spontaneous and cocaine‐induced locomotion, locomotor sensitization were monitored. It was also tested in three standard drug abuse tests i.e. conditioned place preference in rats, self‐administration in monkeys and cocaine discrimination in mice as well as in a physical dependence model.Key Results: Pitolisant did not elicit any significant changes in dopaminergic indices in rat nucleus accumbens whereasModafinil increased dopamine release. In rodents,Pitolisant was without any effect on locomotion and reduced the cocaine‐induced hyperlocomotion. In addition, no locomotor sensitization and no conditioned hyperlocomotion were evidenced with this compound in rats whereas significant effects were elicited byModafinil. Finally,Pitolisant was devoid of any significant effects in the three standard drug abuse tests (including self‐administration in monkeys) and in the physical dependence model.Conclusions and Implications: No potential drug abuse liability forPitolisant was evidenced in variousin vivorodent and primate models, whereas the same does not seem so clear in the case ofModafinil.


  • Brain histamine and schizophrenia: Potential therapeutic applications of H3-receptor inverse agonists studied with BF2.649

    by Xavier Ligneau, Laurent Landais, David Perrin, Johanne Piriou, Marilyne Uguen, Emmanuel Denis, Philippe Robert, Régis Parmentier, Christelle Anaclet, Jian-Sheng Lin, et al.


  • Fluorescent non-imidazole histamine H3 receptor ligands with nanomolar affinities

    by Michael Amon, Xavier Ligneau, Jean-Charles Schwartz, Holger Stark


  • Structural variations of 1-(4-(phenoxymethyl)benzyl)piperidines as nonimidazole histamine H3 receptor antagonists

    by Tibor Mikó, Xavier Ligneau, Heinz H Pertz, Jean-Michel Arrang, C Robin Ganellin, Jean-Charles Schwartz, Walter Schunack, Holger Stark


  • Protean agonism at histamine H 3 receptors in vitro and in vivo

    by Florence Gbahou, Agnès Rouleau, Séverine Morisset, Régis Parmentier, Sylvain Crochet, Jian-Sheng Lin, Xavier Ligneau, Joël Tardivel-Lacombe, Holger Stark, Walter Schunack, et al.

    G protein-coupled receptors (GPCRs) are allosteric proteins that adopt inactive (R) and active (R * ) conformations in equilibrium. R * is promoted by agonists or occurs spontaneously, leading to constitutive activity of the receptor. Conversely, inverse agonists promote R and decrease constitutive activity. The existence of another pharmacological entity, referred to as “protean” agonists (after Proteus, the Greek god who could change shape), was assumed on theoretical grounds. It was predicted from the existence of constitutive activity that a same ligand of this class could act either as an agonist or an inverse agonist at the same GPCR. Here, we show that proxyfan, a high-affinity histamine H 3 -receptor ligand, acts as a protean agonist at recombinant H 3 receptors expressed in the same Chinese hamster ovary cells. In support of the physiological relevance of the process, we show that proxyfan also behaves as a protean agonist at native H 3 receptors known to display constitutive activity. On neurochemical and behavioral responses in rodents and cats, proxyfan displays a spectrum of activity ranging from full agonism to full inverse agonism. Thus, protean agonism demonstrates the existence of ligand-directed active states LR * different from, and competing with, constitutively active states R * of GPCRs, and defines a pharmacological entity with important therapeutic implications.


  • Therapeutic implications of constitutive activity of receptors: the example of the histamine H3 receptor

    by J-C. Schwartz, S. Morisset, A. Rouleau, X. Ligneau, F. Gbahou, J. Tardivel-Lacombe, H. Stark, W. Schunack, C. R. Ganellin, J. M. Arrang

    Some G-protein-coupled receptors display constitutive activity, that is spontaneous activity in the absence of agonist: a proportion of the receptor population adopts a conformation that can bind and activate G proteins. Whereas this was mainly shown to occur with recombinant or pathologically mutated receptors, the physiological relevance of the process has remained debated. We have adressed this question in the case of the histamine H3 receptor, a presynaptic inhibitory receptor regulating histamine release in brain. Having identified a neutral antagonist and inverse agonists with variable intrinsic activity, we show that the native H3 receptor in brain displays high constitutive activity in vitro and, in vivo, controls the release of endogenous histamine. This implies that inverse agonists with high intrinsic activity should be preferred for therapeutic application as “cognitive enhancers” in several psychiatric disorders.


  • A detailed mapping of the histamine H3 receptor and its gene transcripts in rat brain

    by C Pillot, A Heron, V Cochois, J Tardivel-Lacombe, X Ligneau, J.-C Schwartz, J.-M Arrang


  • The Rat H3 Receptor: Gene Organization and Multiple Isoforms

    by Séverine Morisset, Astrid Sasse, Florence Gbahou, Anne Héron, Xavier Ligneau, Joël Tardivel-Lacombe, Jean-Charles Schwartz, Jean-Michel Arrang